Unknown

Dataset Information

0

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study.


ABSTRACT:

Background

Ocular melanoma is the most common primary intraocular malignancy and has a very poor prognosis once liver metastases occur. The aim of this study was to prospectively assess the efficacy and safety of percutaneous hepatic perfusion with melphalan (M-PHP) using the new second-generation (GEN 2) hemofiltration system in patients with ocular melanoma metastases confined to the liver.

Methods

Prospective, single-center, single-arm, phase II study including patients with unresectable ocular melanoma metastases confined to the liver. Treatment consisted of two M-PHP procedures at 6-8 weeks interval. Procedures were performed using the CHEMOSAT (GEN 2) system with 3 mg/kg melphalan. Primary endpoints were overall response rate (ORR) and best overall response (BOR). Secondary endpoints included overall survival (OS), progression-free survival (PFS), hepatic PFS (hPFS), and safety.

Results

Sixty-four M-PHP procedures were performed in 35 patients between February 2014 and June 2017. The ORR was 72%. BOR was as follows: complete response in 3%, partial response in 69%, stable disease in 13%, and progressive disease in 16%. There was no treatment-related mortality. Fourteen serious adverse events occurred. At a median follow-up of 19.1 months (range 5.6-69.5), median OS was 19.1 months and was significantly longer in responders than in nonresponders (27.5 vs. 11.9 months, p < 0.001). The 1- and 2-year OS was 77% and 43%, respectively. PFS and hPFS were 7.6 and 11.2 months, respectively.

Conclusions

M-PHP using the GEN 2 filter can achieve a high ORR and prolonged survival in patients with liver-only ocular melanoma metastases.

SUBMITTER: Meijer TS 

PROVIDER: S-EPMC7801354 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Ocular melanoma is the most common primary intraocular malignancy and has a very poor prognosis once liver metastases occur. The aim of this study was to prospectively assess the efficacy and safety of percutaneous hepatic perfusion with melphalan (M-PHP) using the new second-generation (GEN 2) hemofiltration system in patients with ocular melanoma metastases confined to the liver.<h4>Methods</h4>Prospective, single-center, single-arm, phase II study including patients with un  ...[more]

Similar Datasets

| S-EPMC8758076 | biostudies-literature
| S-EPMC8480350 | biostudies-literature
| S-EPMC8749811 | biostudies-literature
| S-EPMC8469397 | biostudies-literature
| S-EPMC7519914 | biostudies-literature
| S-EPMC2467497 | biostudies-other
| S-EPMC8555734 | biostudies-literature
| S-EPMC8284610 | biostudies-literature
| S-EPMC4354564 | biostudies-literature
| S-EPMC7484678 | biostudies-literature